Table I.

Inclusion criteria.

HLA-A*0201-positive

18–75 years

No fludarabine in previous 3 months

World Health Organization performance status 0–2

Life expectancy 6 months or greater

Haemoglobin ≥70 g/l; neutrophil count ≥0·2 × 109/l; lymphocyte count >0·5 × 109/l; platelet count ≥40 × 109/l

Serum bilirubin, alanine aminotransferase and/or aspartate aminotransferase <3 times upper limit of normal reference range

Creatinine clearance ≥30 ml/min

Patients NOT eligible for haematopoietic stem cell transplantation, with:

AML in CR2 or greater

Good and standard risk AML in CR1 or stable PR (<20% blasts) in patients >60 years

Poor risk AML in CR1 or PR (slow remitters and/or adverse cytogenetics)

AML at first relapse post-HCST in CR or PR following re-induction and consolidation

AML, acute myeloid leukaemia; CR, complete remission; CR1, first CR; CR2, second CR; PR, partial remission; HSCT, haematopoietic stem cell transplantation.